Interactive pharma content is often treated like a production upgrade: more polished modules, richer video, “something clickable.”

But in an HCP portal, interactivity only matters when it helps an HCP complete a task with less effort.

That’s the difference between engagement theater and real utility.

If the portal experience doesn’t shorten time-to-answer, reduce uncertainty, or make the next step obvious, HCPs don’t return, no matter how modern the format looks.

Executive summary

Interactive HCP portal content works when portals help HCPs:

• Find what they need fast (without searching like librarians)
• Move from content to action (a clear next step, not a dead end)
• Use tools in context (decision flows, calculators, and guided exploration)
• Complete workflows that matter (e-sampling requests, virtual detailing journeys)
• Return with less friction (because the portal saves time, not because “it’s nice”)

This article shows what interactive pharma content looks like within an HCP portal and how specialized capabilities such as prescribing tools, digital sampling, and clinical decision support can transform content from “something to consume” into “something to use.”

What is interactive content for HCPs?

Interactive content is any portal experience that adapts to an HCP’s intent and enables them to do something, not just read, watch, or download.

In any HCP portal, that typically means content paired with functionality, such as:

• Guided learning (cases, quizzes, branching scenarios, micro-modules)
• Guided exploration (filters, comparisons, interactive visualizations, “show me what matters”)
• Decision support patterns (calculators, eligibility flows, structured pathways)
• Action workflows (request samples, continue a journey, generate a next step)

So the “interactive” part isn’t the animation. It’s the workflow logic and context that reduces effort and makes the portal useful in that moment.

Interactive pharma content vs. Digital pharma content

A portal can host high-quality digital content and still feel “dead” if nothing helps the HCP reach an outcome quickly.

Key takeaways

• Interactive pharma content is strongest when it behaves like a tool, not a media format.
• The portal’s job isn’t to increase clicks, but to reduce time-to-value for HCPs.
• The most effective interactivity usually happens in small amounts: guided discovery, decision flows, and next-step prompts.
• Specialized capabilities (prescribing tools, e-sampling, virtual detailing) make content actionable.
• If you can’t decide the workflow outcome in one sentence, you probably don’t have interactivity, just decoration.

HCPs need to trust that pharma is in it for the long term, putting patients first and enabling access to medicines. This starts with making sure team incentives, actions, and investments are aligned to solving the biggest problems that HCPs and the health ecosystem are facing.

Dan Johnson, Business Unit Head at Takeda, Switzerland

The four stages of interactive content in an HCP portal

This type of content becomes valuable in an HCP portal when it supports the way HCPs actually move through a task. Most portal journeys follow a simple progression:

• Find what is relevant
• Learn what is necessary
• Decide what applies
• Act on the next step

That’s why we’ll use a four-stage lens:

Discover → Learn → Decide → Act

These stages aren’t a rigid funnel, and they’re not meant to describe every HCP in every moment. They’re a practical way to design interactive pharma content that doesn’t stop at “engaging” and delivers a real outcome within the portal.

The outcome could be completing a micro-module, using a prescribing tool, or submitting a sample request.

In the next sections, each stage is broken down:

• What interactive content looks like in a portal,
• What to build first (the minimum lovable version)
• What to measure beyond views and downloads

Interactive content can’t succeed if HCPs can’t find it quickly. That’s why the first stage isn’t “create better modules,” it’s make discovery effortless.

Stage 1: Discover — help HCPs find relevant content fast

Many HCP portals lose users due to slow discovery. If an HCP can’t quickly confirm “I’m in the right place,” they won’t explore; instead, they’ll bounce, search elsewhere, or go back to whatever tool is already part of their routine.

Interactive content starts at discovery: guided paths that reduce time-to-answer and make the next click obvious.

What it looks like in an HCP portal

• Intent-based entry points instead of one big library: “I need dosing,” “I need clinical trial data,” “I need resources for practice.”
• Search that understands clinical language (synonyms, abbreviations, common queries) and improves with analytics.
• Filter + refine patterns that behave like a tool (e.g., indication, patient data, evidence type, treatment line)
• Guided navigation that suggests where to go next (“If you’re treating X, start here”)
• Progressive disclosure: show the 3-5 most relevant items first, with optional depth, not a wall of assets.
• Contextual recommendations at the end of the page: related content, related tool, or the next workflow (e.g., form evidence to calculator, to sample request)

What to build first

You don’t need personalization engines to improve discovery. Start with:

• A curated “Start here” layer above the library (3-6 tiles mapped to top intents)
• High-signal filters (fewer, better) plus a strong “reset/refine” UX
• A search results page that teaches the portal: track “no results” queries, add synonyms, and improve tagging weekly
• Related content rules (manual curation is fine in phase 1)

What to measure (beyond pageviews)

If discovery is doing its job, you’ll see improvements in:

• Time-to-first-relevant-click (how fast they land on something useful)
• Search success rate (sessions with a click after searching)
• “No results” and repeated searches (signals of poor findability)
• Next-step conversion from context pages (do they continue or exit?)

Stage 1 is where interactive pharma content either earns trust or gets ignored. If discovery feels like browsing a document repository, even the best modules and tools won’t get used.

But when an HCP portal helps users reach the right content quickly, through intent-based entry points, high-signal filters, and search that reflects clinical language, interactivity becomes practical from the very first click.

The goal isn’t to add more content to the library. It’s to reduce time-to-value and make the next step obvious. Once discovery works, you can build deeper experiences on top of it, which is where Stage 2 comes in: interactive learning that feels like clinical thinking, not e-learning.

Once discovery works, the next barrier is time. HCPs won’t “consume content” the way teams expect; they’ll use what fits the moment. That’s where Stage 2 comes in: learning experiences designed around real clinical thinking, not long-form e-learning.

Stage 2: Learn — interactive learning

Once HCPs can find the right path, the next question is whether the portal helps them learn in a way that matches how they think and work.

Stage 2 is where interactive content either becomes genuinely useful or starts to feel like “training content” that gets postponed indefinitely.

In an HCP portal, learning works best when it’s short, scenario-led, and decision-shaped. HCPs rarely want to “take a course.” 

They want to answer a question, confirm an approach, or understand why something matters, quickly.

What it looks like in the real world

• Case-based micro-modules: a brief patient scenario → a decision point → rationale → evidence snippet → takeaway.
• Branching pathways: “If A, show this; if B, show that”; enough to feel tailored without being complex.
• Knowledge checks that unlock depth: 1-3 questions that lead to “show me the why,” not a score for the sake of scoring.
• Interactive visuals that let HCPs explore (toggle endpoints, filter subgroups, compare outcomes) instead of static slides.
• Save/resume and “continue where you left off” so learning respects fragmented time.

What to build first

You don’t need a full LMS to do Stage 2. Start with:

• One reusable module template (same components every time: scenario → decision → rationale → evidence → summary)
• 3-5 micro-cases around high-frequency portal intents (patient selection, dosing moments, monitoring, switching).
• A basic progress state (completed/ in progress/ saved) and a “continue” entry on the portal home.
• One interactive component per module (a branching choice, a simple calculator, or a toggleable visual).

What to measure (beyond completion rate)

Completion is useful, but Stage 2 success is about continued value:

• Drop-off point by step (where do they quit: scenario, evidence, quiz, summary?)
• Time-to-complete (too long = avoidance; too short = superficial)
• Return-to-learn rate (do they come back within 7-14 days?)
• Next-step conversion (after the module, do they go deeper?)

Stage 2 is where interactive pharma content proves it can be more than “engaging.” If learning experiences are short, scenario-led, and built around real decision moments, they stop feeling like content to consume and start feeling like help.

Once you reliably move an HCP from question → context → takeaway → next step, you’re ready for Stage 3 — where interactivity offers clinical decision support through prescribing-adjacent tools and structured pathways. 

If Stage 2 helps an HCP understand what matters, Stage 3 is where portals help them apply it. This is the shift from interactive learning to interactive guidance; tools and pathways that support decisions with clear boundaries and references.

Stage 3: Decide — interactive content becomes guidance

Stage 3 is where interactive pharma content stops being “education” and becomes decision support within the portal. Not in the sense of replacing clinical judgment, but in removing friction around applying information: confirming eligibility logic, checking practical steps, and structuring what to consider next.

This is also where teams need the clearest guardrails: prescribing tools must be designed to be accurate, transparent, and compliant, with clear references and boundaries.

What it looks like in an HCP portal

• Guided pathways (scenario → step-by-step considerations → relevant references): essentially a navigable checklist that helps an HCP confirm “what applies here?”
• Eligibility/ appropriateness flows: structured questions that map to clinical criteria and route the HCP to the right content or evidence section.
• Calculators: dosage-related math, titration support, risk scores, or monitoring schedules, always paired with assumptions and references.
• Interactive summaries of complex information: “show me the key points, then let me expand.”
• Next-best-step prompts: after the output, the portal suggests the most relevant follow-up (e.g., safety section, patient materials, sample request, etc.)

What to build first

Start with one high-frequency “decision moment” and build a single, excellent tool rather than five mediocre ones:

• One guided flow for a common scenario (patient section, switching, initiation, monitoring)
• A simple calculator template with:
  • Clear inputs and units
  • Visible assumptions
  • A “how this was calculated” hint
  • Links to supporting references

• A structured output screen that offers:
  • The result
  • What to check next
  • Direct links to the exact supporting content (not a generic PDF download)

What to measure (beyond clicks)

Prescribing support tools should be measured like utilities:

• Tool completion rate (start  → output)
• Repeat usage (do HCPs come back to the tool?)
• Output-to-next-step conversion (what do they do after getting the result?)
• Error and abandonment signals (confusing inputs, missing units, unclear outputs)

Stage 3 is where interactive content earns a “utility” role in an HCP’s routine. When portals provide explainable pathways and calculators that help HCPs apply information quickly, with clear references and guardrails, interactivity becomes guidance rather than decoration.

From there, the next step is Stage 4: turning guidance into action through e-sampling and virtual detailing workflows.

Once an HCP has clarity, the portal needs to support momentum. Otherwise, the journey ends with “good to know.” Stage 4 is about turning insights into next steps through workflows such as e-sampling and virtual detailing.

Stage 4: Act — interactive content becomes a workflow

In Stage 4, we move on from content being “useful” to becoming operational. If a portal can help an HCP discover, learn, and decide, but can’t support a next step, the experience still ends like a library: informative, then forgotten.

In an HCP portal, “Act” usually means two things:

• Enabling a compliant e-sampling workflow, and/or
• Enabling a coherent virtual detailing journey that continues beyond a single interaction.

This is where portal design, integration, and governance matter as much as content.

E-sampling — turning interest into a compliant request flow

What it looks like in an HCP portal

• A contextual CTA (“Request a sample”) placed where intent is highest: after patient selection, dosing, or a relevant module, not buried in navigation.
• A guided flow that feels like a form, only where it must:
  • Validate HCP identity/eligibility (where required)
  • Capture request details
  • Confirm and create a traceable record
• A status view: what was requested, what’s pending, and what happens next.

What to measure

• Request start → completion rate (drop-off by step)
• Time-to-fullfillment (where the process slows down)
• Repeat requests per HCP (a proxy for workflow usefulness)
• Support requests/ failed requests (signals of friction)

Virtual detailing — from one-off content to a guided journey

Virtual detailing works best when it’s not treated as “a video in the portal.” The portal’s value is continuity: the ability to move an HCP through a short, modular journey that adapts to what they care about and supports follow-up.

What it looks like in an HCP portal

• A choose-your-path journey made of short segments:
  • Overview → clinical scenario → evidence
  • Deep dive → safety/monitoring → practice tools
• Rep-enables continuity:
  • Pre-call: what the HCP viewed, what to recommend next
  • Post-call: recap + next module + resources
• Interaction mechanics that keep it alive:
  • Save questions for follow-up
  • Request additional information
  • Continue where you left off

What to measure

• Segment completion and progression (do they move to the next step?)
• Return rate to the journey within 14 days
• Follow-up actions (requests, saves, booked interactions, downloads where relevant)
• Drop-off points (which segment loses them and why)

Stage 4 is where interactive content becomes a portal capability, not just a content strategy. When e-sampling and virtual detailing are designed as in-context workflows, with status, continuity, and measurable next steps, the portal stops being “a place to visit” and becomes “a place to get things done.”

When the four stages work together, the portal stops behaving like a content repository and starts behaving like an experience:  discover → learn → decide → act, with measurable outcomes at each step. The checklist below summarizes what to validate before scaling.

Recap: a practical checklist for interactive pharma content in an HCP portal

You can use this as a quick check before you build interactive content in your portal:

Discover

• Do you have intent-based entry points?
• Can an HCP find a relevant asset in under a minute?
• Are filters high-signal and consistently tagged?

Learn

• Are learning modules scenario-led and 3-7 minutes by default?
• Can users save and resume without losing progress?
• Does each module end with a clear next step?

Decide

• Are decision tools explainable and easy to complete?
• Are inputs/outputs unambiguous?
• Do you have a plan for versioning and content currency?

Act

• Can users complete an e-sampling request without leaving the portal?
• Is there a track-my-request experience?
• Is virtual detailing build as a modular journey, not a single long presentation?

Measurement

• Are you tracking completions and next-step conversion, not just views?
• Do you review search queries and drop-offs monthly and iterate?

Key takeaways

• Interactive pharma content works when it behaves like a tool.
• The portal’s job is to reduce time-to-value: find fast, learn fast, decide confidently, act easily.
• The strongest experiences combine interactive content with portal functionality.
• Measure success through completion, repeat usage, and next-step conversion — not views alone.
• If you build interactivity with clear outcomes and governance, the portal becomes a place HCPs return to because it saves them time.

The post What does interactive pharma content look like in an HCP portal? appeared first on Digitalya.

Pharma digital companions are digital tools designed to support patients and healthcare professionals throughout the treatment journey. These solutions typically include mobile apps, AI-powered assistants, symptom trackers, and remote monitoring platforms that help improve treatment adherence, patient education, and real-world data collection.

In recent years, pharmaceutical companies have increasingly adopted digital companions as part of broader digital health strategies. These platforms enable continuous patient engagement, remote monitoring, and personalized treatment support while generating valuable insights for healthcare providers.

Key capabilities of pharma digital companions include:

• Patient education and therapy support
• Symptom tracking and medication reminders
• Remote health monitoring through connected devices
• Telehealth communication with healthcare professionals
• Real-world data collection for treatment optimization

According to Deloitte, disease management applications were valued at $8.7 billion globally in 2022, with projected annual growth of 12.3% through 2030. This rapid expansion highlights the growing role of digital companions in modern healthcare ecosystems.

For pharmaceutical companies, digital companions represent an opportunity to move beyond traditional product-centric models toward patient-centric digital ecosystems that improve outcomes, engagement, and long-term treatment success.

1. What are pharma digital companions?

First things first. What are these newly emerged companions? They do sound like a high-tech pet or the sort of robot friend that keeps you company and does some chores around the house.

Pharma digital companions are digital health tools designed to support patients and healthcare professionals throughout the treatment journey. These platforms typically include mobile apps, AI-powered assistants, symptom trackers, and remote monitoring systems that help patients follow treatment plans, track health indicators, and communicate with healthcare providers.

Unlike general healthcare apps, pharma digital companions are usually connected to a specific therapy, disease area, or patient support program, helping pharmaceutical companies improve treatment adherence and collect real-world data about patient outcomes.

Common capabilities include:

• medication reminders and adherence tracking
• remote monitoring of vital signs
• patient education and disease management resources
• telehealth communication with clinicians
• data collection for real-world evidence

2. The growing significance of digital companions in pharma

In recent years, the significance of digital companions in healthcare has surged, driven by the increasing demand for personalized and accessible patient support. A report by Global Data on Mobile Health Apps shows that, by 2030, the market for regulated medical apps is expected to reach US$12.1 billion.

Moreover, according to Deloitte, in 2022, disease management apps were worth USD 8.7 billion on the global market, with a projected annual growth of 12.3% from 2023 to 2030.

These companions offer a myriad of benefits, ranging from enhancing patient engagement and adherence to gathering real-world data for insights and improved outcomes. As the healthcare landscape continues to evolve, digital companions are poised to play an even more integral role in patient care and management.

How pharmaceutical companies use digital companions

Pharmaceutical companies deploy digital companions across several areas:

• Patient support programs – helping patients manage treatment side effects and adherence
• Clinical trials support – collecting real-world patient data
• Therapy management – monitoring patient progress during long treatments
• Disease education platforms – improving patient understanding of conditions
• Digital therapeutics ecosystems – combining software with medical treatments

Out Now

HCP Portal Audit: Find Out Where Your Portal Falls Behind in 2026

Get access to a comprehensive audit and in-depth analysis of 28+ HCP portals across Europe and the US.

Get the report

3.  Benefits of pharma digital companions

Digital transformation in pharma would not take place, evidently, if there weren’t clear benefits for all the categories involved: patients, healthcare professionals, health organizations, and pharma companies. So, let’s take a look at what the main benefits are:

3.1 Enhancing patient engagement and adherence

One of the main concerns for physicians worldwide and a key factor in failing to obtain the expected health outcomes is patients’ inconsistency in following the prescribed treatment. Thus, the primary benefit of pharma digital companions is their ability to foster greater patient engagement and medication management.

By providing personalized support and resources, patients engage more and take an active role in managing their health, leading to improved compliance and better health outcomes.

3.2 Improving treatment outcomes and patient health

Digital solutions such as patient companion apps enable continuous monitoring and support, allowing the healthcare professional to track patient progress in real-time and intervene when necessary. This proactive approach not only improves treatment outcomes but also enhances patient health by ensuring timely interventions and adjustments to care plans.

Remote health monitoring capabilities further strengthen this benefit. By collecting patient data from connected devices and health applications, clinicians gain a continuous view of the patient’s condition rather than relying solely on occasional consultations.

This approach is particularly valuable for patients with chronic conditions who require ongoing monitoring and treatment adjustments. Real-time data allows healthcare providers to detect anomalies earlier, personalize treatment plans, and reduce the risk of complications or hospital readmissions.

3.3  Gathering valuable real-world data

Another significant advantage of digital companion apps is their ability to gather valuable real-world data. By tracking patient interactions, symptoms, and treatment responses, these digital health solutions provide valuable insights into patient behavior, preferences, and treatment efficacy, which can inform future decision-making and product development.

3.4 Expanding patient education and support

Digital companion apps serve as a valuable resource not only for patient support but also for keeping HCPs up to date with the latest medical developments. 

Regarding patients’ benefits, they can offer access to a wealth of information, resources, and tools to help them understand their condition and treatment options. By providing personalized education and support, these companions empower patients to make informed decisions about their health and treatment.

3.5 Reducing healthcare costs

Because pharma digital companions engage patients in following their treatment and monitoring their health, the result is increasing adherence to treatment and proactive management of health conditions.

Thus, they can potentially reduce healthcare costs associated with hospitalizations, emergency room visits, and complications. By maintaining medication adherence and keeping patients better informed, these companions help to minimize the burden on healthcare systems and resources.

Remote monitoring solutions also contribute to cost reduction by minimizing unnecessary clinical visits and enabling healthcare professionals to prioritize cases that require immediate attention. Medical teams can analyze patient data remotely and intervene only when needed, optimizing resource allocation and reducing the operational burden on healthcare facilities.

4. Types of pharma digital companions

Pharma digital companions come in various forms, each serving specific purposes and catering to different aspects of patient care and management. Some key trends in the health industry regarding digital companions are:

4.1 Informational and educational companions

A digital patient companion provides access to educational resources, information about their condition, treatment options, and lifestyle recommendations.

On the healthcare professional side, educational companions capture value by bringing much-needed information on the specific topics that interest each HCP. Mind that their spare time is very limited, and they focus on getting maximum quality insight from every second.

At the same time, they are perfectly aware of the marketing strategies behind any pharma company’s approach. Thus, HCPs can become suspicious and even reluctant to interact with push content sent by email or other digital technologies. Pharma digital companions can strengthen the trust between HCPs and your health company by acting as a supportive presence, ready to offer relevant content without any “sales” scheme in a human-like interaction.

4.2 Symptom tracking and management companions

These companions enable patients to track symptoms, medication adherence, and other vital health metrics, providing valuable insights into their condition and treatment progress.

IoT in healthcare develops quickly with remarkable results. Digital therapeutics paired with medical and medication devices gather health data, run symptom analyses, and can alert doctors when necessary about a patient’s state of health.

Timely measures can prevent problems from getting worse. Digital drug companions can help with dosage calculations. This way, patients with memory issues (or just light-mindedness) are sure to get the correct measured values for their prescription drug and follow the right treatment. 

Let’s not forget the patients with chronic diseases. In the United States, there are approximately 147 million people living with chronic conditions. Extrapolate that number to the entire world, and you’ll get an idea of how much such a digital solution is needed. It is, in fact, a public health issue.

Pharma digital companions can help these patients rigorously follow their life-long treatment plans. By tracking behavior, they can offer personalized feedback and help patients maintain care activities that can improve health outcomes. Diabetes is a condition for which digital health tools are largely implemented, starting with automatic blood sugar measurements and alerts on a mobile app.

4.3  Telehealth and remote monitoring companions

Telemedicine has gained much terrain in the past years and constantly proves its efficiency. By using such companions, patients become digital patients that HCPs can monitor and communicate with remotely.

These companions facilitate virtual consultations, remote monitoring of patient health metrics, and communication between patients and healthcare providers, enabling timely interventions and adjustments to care plans.

For routine checks and follow-ups, these pharma digital companions build a virtual bridge between doctor or nurse and patient, without the need for physical presence and all the inconvenience that comes with it. All those involved gain precious time, save money (if travel costs are involved), and get answers fast enough to prevent a condition from worsening. 

Remote monitoring is often enabled by connected medical devices and software platforms that collect and analyze patient health data in real time. These systems allow healthcare providers to track vital physiological indicators such as heart rate, blood pressure, blood glucose levels, or body temperature without requiring the patient to visit a medical facility.

Some common remote monitoring applications integrated into digital companion solutions include:

• Vital sign monitoring, where wearable devices track parameters such as heart rate or blood pressure and alert clinicians if abnormal values appear.
• Continuous glucose monitoring, particularly useful for diabetes management, where sensors automatically track glucose levels and correlate them with lifestyle factors such as diet, stress, or medication.
• Neurological monitoring systems, capable of identifying early signs of stroke or abnormal brain activity through remote tracking.
• Medication monitoring, which helps patients follow complex treatment regimens and provides physicians with insights into treatment effectiveness.
• Pediatric monitoring systems, allowing caregivers and clinicians to track health parameters for infants and children who cannot easily communicate symptoms.

These capabilities transform digital companions from simple informational tools into continuous care platforms, helping healthcare professionals detect potential complications earlier and intervene before a condition deteriorates.

Pharma digital companions vs remote health monitoring software

In practice, remote monitoring tools often become part of pharma digital companions, enabling continuous patient care outside hospital environments.

5. Developing and implementing effective pharma digital companions

All things nice, but how do you actually put such a digital companion on the market? As many things in life that seem complicated, with proper planning and the right people and set of skills, medical app development becomes a fine possibility.

Key elements of successful pharma digital companion development include:

1. User-centered design for patients and clinicians
2. Integration with electronic health record systems
3. Secure health data infrastructure
4. Evidence-based design and evaluation

5.1 User-centered design and patient involvement

User experience, whether we talk about patient experience or HCPs as users, is paramount.

To ensure the effectiveness and usability of digital companions, it’s essential to involve the end user in the design process and prioritize user-centered design principles, such as the patient journey.

Digital health tools must be intuitive and accessible, especially considering that many patients using these solutions may have medical conditions. Some might have their concentration, memory, or physical abilities affected. Designing simple interfaces and clear workflows is essential to ensure that both patients and healthcare professionals can use the platform without additional cognitive burden.

5.2  Clear and personalized communication

Digital companions should communicate information clearly and personalized, taking into account the individual needs and preferences of patients and HCPs. We are bombarded by information all day (even in our sleep sometimes).

Promotional and irrelevant messages account for most of this enormous brain load. No one wants another app that adds to the information they already receive. However, if you respect their mental space and real needs, you’ll win the users’ appreciation and loyalty.

That is not to say you shouldn’t apply marketing strategies to gain market access, but it should deliver customized messages that address relevant needs. AI in pharma marketing has come a long way, and it is the answer to craft personalized approaches that offer answers instead of burdens.

5.3  Integration with existing healthcare systems

Digital companions should seamlessly integrate with existing healthcare systems and workflows to ensure smooth implementation and adoption by healthcare providers. The healthcare ecosystem is complex, but everything works better when connection and collaboration are enabled.

Integration between pharma digital companions and healthcare systems will first and foremost improve patient outcomes, the general state of health, and the health economy. Secondly, but equally important, the overall approach will help medical and healthcare staff act more fluently, reducing unnecessary waste of time, frustration, and fatigue.

For example, remote monitoring solutions generate significant volumes of patient data. 

To be truly useful, this information must integrate with electronic health record (EHR) systems and other healthcare platforms so that clinicians can interpret it in the broader context of a patient’s medical history.

Without such integration, valuable data may remain isolated and difficult to act upon. 

5.4 Data security and privacy

Protecting patient data is crucial. Digital transformation in pharma companies should adhere to strict data security and privacy standards to safeguard patient information and comply with regulatory requirements. Analyst reports on patient populations are important for developing medicine and innovative treatments. Still, the way they are obtained should be ethical, and the privacy rights of individuals should be respected.

5.5 Evidence-based design and evaluation

Needless to say, the design and efficacy of digital companions should be based on scientific evidence and undergo rigorous evaluation to ensure their effectiveness in improving patient outcomes and engagement. When dealing with people’s health, nothing should be left to hazard.

6. Case studies of successful pharma digital companions

6.1 Examples of companions that have improved patient outcomes and engagement

In 2020, Sanofi partnered with Taiwanese company Health2Sync to provide integrated, digitized diabetes management by developing patient management software for healthcare professionals, as well as a mobile app for patients. This digital health partnership led to implementing the diabetes digital companion in clinics and hospitals contracted by Sanofi. In May 2022, over 10000 insulin patients and more than 200 clinics had onboarded the digital companion program. The app resulted in improved glycemic control and increased patient adherence to treatment plans.

The utility of this approach becomes clear given that a 2019 report published by the Taiwan Association of Diabetes Educators in the Diabetes Atlas regarding the Taiwan population showed that less than 40% of diabetes patients can reach HbA1c <7%. The rate of insulin administration in Taiwan is 12%, a low number compared with Europe and the USA. Moreover, in Taiwan alone, there are over 2.2 million diabetes patients.

6.2 Insights from pharma companies that have effectively implemented digital companions

Pfizer is a good example of a pharma company that successfully implements digital companions. In 2019, they launched the Mabu wellness coach, which is a patient engagement robot that functions on artificial intelligence (AI), built by Catalia Health.

The Mabu patient companion “talks” with patients, asks them how they feel, and answers their questions about the treatment. The companion is linked to an Insights Platform that sends valuable information to clinicians, so the caregivers can intervene in time to support the patient’s specific needs in their treatment journey and manage symptoms in real time.

Pfizer also acquired ResApp Health for $75 million, in their pursuit to diagnose and manage respiratory diseases using AI technology. The market data shows that the company’s revenues rocketed by 3503% in 2022 compared to 2020. 

For patients living with cancer, Pfizer developed the LivingWith app – yet another digital patient companion. It connects patients with an oncology support system. It helps them remember and keep important information received from their doctors and also share relevant information with caregivers, family, and friends.

7. Future of pharma digital companions

As digital technologies continue to advance and pharmaceutical companies invest massively in digital, the future of pharmaceutical digital companions looks promising.

7.1 Emerging trends in digital companion technology

Advancements in AI, machine learning, and natural language processing enable more personalized and adaptive digital companions. They become capable of learning from patient interactions and adapting their recommendations over time to match precise needs in real-time, whether it is detecting symptoms, adapting treatment dosage, answering questions, or even providing psychological support.

7.2 Potential applications of artificial intelligence and machine learning

When used by a large enough population of patients, such AI-powered digital companions can use data to build predictive models for health outcomes. They can identify potential complications early on and recommend personalized interventions to prevent adverse events. Imagine that in the near future, with the help of digital companion apps, patients can access patient support programs and digital therapy from the safety of their homes quickly and easily.

7.3 The role of digital companions in the precision medicine era

We have entered the era of precision medicine. It is with the help of digital companions and data analytics that clinicians and pharma companies will be able to tailor treatments and interventions to the individual needs and genetic makeup of patients, enabling more targeted and effective healthcare delivery.

8. Conclusion

Key takeaways

• Pharma digital companions are digital tools designed to support patients and healthcare professionals during treatment.
• They improve patient adherence, engagement, and treatment outcomes.
• Digital companions often combine education, symptom tracking, telehealth, and remote monitoring capabilities.
• Pharmaceutical companies increasingly use them to collect real-world patient data and optimize therapies.

Emerging technologies such as AI, machine learning, and IoT devices will further expand the role of digital companions in healthcare.

It is safe to say that pharma digital companions represent a paradigm shift in patient care and medication management, even in public health. They offer personalized support, education, and engagement all in one throughout the patient journey.

By leveraging the potential of digital technologies, pharmaceutical companies can empower patients, improve treatment outcomes, and finally drive better health outcomes. As we continue to embrace innovation and advance digital companion technology, the future of healthcare looks brighter than ever before.

FAQs

The post Pharma Digital Companions – how to leverage the potential appeared first on Digitalya.

Pharma can borrow these patterns, even with compliance constraints, if we translate them correctly.

Executive summary

HCP engagement grows when portals help HCPs:

• Access what they need with minimal friction
• Activate quickly (first useful action happens fast)
• Get value that supports real clinical work
• Return by habit because the portal reliably saves time and improves decisions

This article breaks HCP engagement into a simple ladder:

Access → Activation (first useful action) →  Value →  Habit

and maps proven cross-industry patterns to each stage, so that pharma teams can improve adoption and return visits.

What is HCP engagement in pharma?

HCP digital engagement is the ability of a pharma brand’s ecosystem, especially its HCP portal, to help healthcare professionals complete meaningful tasks (learn, decide, download, request, follow up) and choose to return over time.

Engages HCPs beyond just “consume content.” They:

• Find trusted information fast (and can verify it)
• Discover relevant updates without digging
• Use tools or resources that reduce effort in their workflow
• Build confidence that the portal is worth coming back to

Engagement is not pageviews, time on site, or “more content.” These metrics can rise even if HCPs feel frustrated or unsupported.

HCP engagement vs. HCP digital experiences 

A portal can have a nice experience and still fail to drive engagement if it doesn’t deliver ongoing value, support real tasks, or reduce workflow friction.

If you want to go deeper on the “quality of interaction” side, here’s a breakdown of what makes a strong HCP digital experience.

Key takeaways

• Engagement starts (or dies) at access: registration and login friction can prevent engagement before it begins.
• Activation depends on speed-to-value. The first useful action must happen quickly.
• Value requires trust and relevance. Content must be current, structured, and easy to verify.
• Habit is built through discovery: recommendations, smart search, and “next best content” patterns matter.
• Cross-industry patterns work in pharma only when translated into compliant, portal-specific workflows.

Andrew Binns, Head of Digital and Innovation at AstraZeneca UK, interestingly said in the webinar Why HCPs Aren’t Engaging with your Portal — Can AI help?:

What we really want is to give each doctor an individual, unique, helpful, resonant experience, and the more refined we get at that, the better the experience will be. That’s where the power of HCP portals is. But it’s a challenge, it’s tough. We’ve got so many issues within this sector that other sectors don’t have; things like compliance, the sign-off process, which makes it incredibly difficult to create these individualized experiences if the MLR review process means they’ve got to see the content in situ. (…) That’s the world we live in, and it’s brilliant and completely fantastic that we live in this very compliant world because we’ve got to be protective over everything that goes out into the world.

Andrew Binns, Head of Digital and Innovation at AstraZeneca UK

Before diving deeper, it’s important to have the same understanding of HCP preferences and behaviors.

Stage 1: Access — engagement starts before the first click

Effective HCP engagement can’t happen if healthcare professionals can’t get in quickly, find what they need, and trust they’re in the right place. Access is more than just having a portal. It’s the experience of entry and orientation.

HCPs are time-constrained and highly goal-driven.

They prefer digital channels for medical information, with 52% of physicians considering websites essential and favoring them as a source.

That means every step before value—unclear navigation, slow performance, confusing content structure, lengthy registration—reduces the likelihood of engagement.

What “Access” includes in pharma HCP engagement

Access is the combination of four things:

• Entry friction — registration, verification, login, password resets
• Orientation — can an HCP immediately understand what the portal offers and where to go?
• Findability — search + navigation that surfaces the right content fast
• Trust signals — medical ownership, content relevance, references, and clarity around the intended audience.

Segmenting access — not every HCP enters the same way

To build trust and engagement, access has to reflect real audience differences:

• Primary care vs. specialists — different depth, different urgency, different content paths
• Region and tech ecosystem — local compliance, local platform constraints, existing workflows
• Digital maturity — some HCPs want fast self-serve; others still rely on human touchpoints

This is why one-size-fits-all portals often underperform. They force all users down the same path, with the same navigation and content structure.

Segmenting access is the first step toward building personalized HCP journeys that actually drive trust and repeat use.

Why portals still matter for HCP digital engagement strategies 

HCP portals are still the best place for measurable HCP engagement (adoption + return visits). They combine trusted content, tools, and data-driven discovery in one controlled environment.

When portals work, they are more than content repositories. They:

• Support field medical and omnichannel programs with consistent, trackable touchpoints
• Make it easier to understand what different HCP segments actually need (behavior + intent signals)
• Create the foundation for the compliant personalization later (without guessing)

But here’s the catch: portals only become engagement engines if the access layer is frictionless. Otherwise, they become content repositories behind a login, and engagement stalls before it begins.

Portals are a great way to collect data, making it easier to adapt strategies to engage HCPs.

At the core of digital HCP engagement, pharma portals must be intuitive, user-friendly, and integrate with other digital channels to provide a cohesive, comprehensive experience.

Unfortunately, our recent audit of 28+ European and US portals revealed that many pharmaceutical brands lack in offering user-friendly experiences.

Once access is resolved, the next question is activation: does the HCP complete a first useful action quickly, or do they leave before value is shown?

Out Now

HCP Portal Audit: Find Out Where Your Portal Falls Behind in 2026

Get access to a comprehensive audit and in-depth analysis of 28+ HCP portals across Europe and the US.

Get the report

Stage 2: Activation — get the first useful action to happen fast

Access gets an HCP into the portal. Activation is what happens next: do they complete a first meaningful action quickly, or do they get stuck and leave?

SaaS companies excel in user onboarding by minimizing friction. An effective onboarding process can boost customer retention by 50%, whereas poor onboarding can lead to a 40-60% dropout rate.

In pharma, the activation moment is often blocked by the same friction point: onboarding that asks for too much, too early.

The activation problem in pharma portals

Many pharma portals still rely on lengthy registration forms, sometimes with more than 15 fields. And that’s before an HCP can do anything useful. 

That’s a high drop-off trigger, especially when the value proposition isn’t immediately visible.

Example of a lengthy registration form used on a pharma portal

These friction points repeatedly appear in portal benchmarks — here are the hidden reasons behind low HCP portal adoption (and what AI can realistically improve).

As Rob Verheul, CEO of UI/UX agency Graphite Digital, puts it:

The drop-off in registrations and logins is enormous, so we need to give value to people and reasons to log in.

Rob Verheul, CEO, Graphite Digital

Cross-industry pattern: progressive onboarding

SaaS onboarding doesn’t treat the registration form as a compliance ritual. It’s a conversion step that must be earned. The idea is simple:

1. Collect only relevant information upfront — eliminate non-essential fields in the first step. Move “nice-to-have” data to a later stage.
2. Offer gradual profile building (progressive profiling) — let HCPs enrich their profile over time rather than during the first session.
3. Make the form feel shorter — use progress indicators, checklists, and clear “why we’re asking this” microcopy to reduce perceived effort.
4. Use interactive, low-friction UI patterns — tools like Officevibe use interactive form patterns that make completion feel quick and guided, not like paperwork. Portals can use the same design logic, icons, smarter field types, and friendlier interactions to increase completion rates.

Activation KPIs (what to measure)

If this is truly about HCP engagement, track activation like a product team would:

• Registration completion rate
• Login success rate (including password reset success)
• Time to first useful action (e.g., first resource view/ download/event registration)
• First-session task completion rate (by segment)

Once activation is solved, engagement becomes a content and discovery problem: do HCPs consistently find what they need fast, and does the portal feel worth returning to?

Stage 3: Value — make the portal worth returning to

After access and activation, HCP engagement becomes a value question: does the portal reliably save time, reduce uncertainty, or support clinical work?

If the answer is sometimes, return visits stop. If the answer is sometimes, engagement becomes a habit.

Cross-industry leaders build value through one core capability: fast discovery of the most relevant next thing, without making users search like librarians.

The value problem in many HCP portals

Even when the content is high quality, portals often fail on delivery:

• Content is hard to find (weak search, unclear taxonomy, too many clicks)
• Content feels generic (no relevance cues for role, specialty, interest)
• The portal behaves like a repository, not a service layer

In practice, that means HCPs bounce back to external sources, not because they don’t trust pharma, but because the path to value is shorter elsewhere.

Cross-industry pattern: recommendations that reduce effort

Amazon doesn’t rely on users to navigate categories perfectly. It reduces choice overload by continuously answering: “What should you look at next?”

Pharma portals can apply the same underlying logic by guiding HCPs toward:

• The most relevant new data since their last visit
• Content linked to their specialty and interests
• Next-step resources after a page view (e.g., summary → full data →  patient resource → downloadable slide deck)

Practical value tactics for HCP portals

• Add “Next best content” modules — place recommendations at the end of key pages (like “Related clinical data,” “Commonly used resources,” “What changed since the last update”)
• Build value around tasks, not pages — organize journeys around what HCPs try to do (verify, learn, download, register, request) rather than around internal content types.
• Make relevance visible — use short relevance cues: “Updated last month,” “New trial publication,” “For cardiology,” “3-min summary.” This increases trust and speeds decisions.
• Improve discovery with smart research — search should handle medical terminology, synonyms, and intent (not just exact keyword matches). If the search fails, engagement fails, because the portal becomes hard work.

An AI-powered search bar can show more suggestions based on what’s searched.

These personalized recommendations can go even further. By using browsing history, interactions, and other data points (such as email interactions), you can offer a personalized recommendation system for your homepage.

Just as each refresh on Amazon.com changes the items based on past interactions, the same can be true for pharma portals—making it easier for people to resume where they left off, dig deeper into related topics, and uncover unseen content that might help them.

Studies confirm that 80% of consumers are more likely to do business with a company that offers a tailored experience. Plus, 90% find personalization very appealing.

This is the foundation of personalized HCP engagement — but it needs the right governance and data boundaries.

Cross-industry pattern: conversational discovery (AI chat) for “find the right thing fast”

In many digital products, users don’t engage more because the content is better, but because it’s easier to find the right thing quickly.

Conversational interfaces reduce search and navigation effort by allowing users to describe their intent in plain language.

The SaaS industry has perfected the art of ongoing support and digital engagement through AI-powered chatbots.

For example, Intercom’s Fin handles up to 87% of customer queries independently, with customers noticing double-digit gains in engagement.

Considering that 70% of HCPs say they’re interested in live chat functionalities. Yet, most portals completely lack this feature. Exploring the benefits of AI chatbots can prove to be a great addition to the digital stack.

How can this be translated into the pharmaceutical industry? 

In HCP portals, the safest and most effective version isn’t “Ask AI anything.” It’s conversational discovery: a guided layer that helps HCPs find approved portal resources faster.

1. Instant support – AI chatbots can provide valuable insights and real-time answers to drug interaction queries and dosage calculations, and offer access to the latest studies.
2. Content discoverability – AI chatbots can offer faster access to relevant content by allowing HCPs to search or ask using natural language.
3. Data-driven personalization – Analyze user behavior to personalize content.
4. Enhanced marketing results — Use chatbots to trigger timely feedback and share resources, complementing traditional communication methods such as email and field medical team visits.

Other companies already see results. 

Sephora’s Kik chatbot increased survey responses by 70% compared to emails. Getting feedback when someone is already interacting with your brand is easier than when you are interrupting their day-to-day.

The biggest fear with custom-made GenAI chatbots is regarding regulations. The solution is to use machine learning and train the AI on your knowledge base to ensure accurate answers. 

Moreover, such AI systems can adopt your brand’s tone of voice, adhere to policies, and even integrate with platforms like Veeva CRM to update HCP interactions—fueling further personalization and improving engagement with HCPs effectively.

All the generated data can then fuel the recommendation system within your portals, leading to even more customized and unique digital experiences.

If you’re considering this capability, here’s a practical guide to GenAI chatbots for HCP portals.

Out now

The State of AI in Pharma: Trends, Benchmarks, and What's Next

Get our exclusive market research, featuring insights from 200+ leaders across the EU, US, and Asia.

Get the new report

Stage 4: Habit — create reasons to return without being pushed

If Stage 3 (Value) answers “Is this portal worth it?” then Stage 4 (Habit) answers “Why should I come back next week?”

In other industries, habit is built through repeatable value loops: short-form content that fits busy schedules, clear progression, and lightweight interactivity that keep users moving.

Cross-industry pattern: interactive formats that reward repeat engagement

In streaming and modern digital learning, retention improves when platforms make it easy to start and finish tasks and make it obvious what to do next. The same logic applies to HCP engagement, especially for busy users who don’t have time to explore a portal.

Top platforms increase return behavior by:

• Breaking content into short, structured modules (easy to start, easy to finish)
• Using interactivity to keep attention (quizzes, checkpoints, “choose what you want next”)
• Creating a sense of progression (“continue where you left off,” “new since last time”)

How to translate it for pharmaceutical companies 

Habit-building in HCP portals comes from formats and features that fit real HCP workflows:

• Micro-learning modules

Turn long resources into short “decision-support”  units: summary → key data →  references → next action.

• “New since your last visit” updates

Give HCPs a reason to return by highlighting what changes: new data, updated resources, new versions.

• Series over one-offs

Build repeatable bundles (“Monthly evidence update,” “Case discussion series,” etc) so returning feels purposeful, not random.

These habit loops are much easier to sustain with dynamic content for HCP portals — content that updates, recombines, and stays current.

No one on planet Earth wakes up in the morning and thinks, ‘I want to go to a pharma website and get a personalized experience.’ And likewise, I don’t go on to Netflix and think, ‘This is an incredible personalized experience for me.’ What I do think is ‘This is brilliant, I’m seeing content that’s relevant and useful to me,’ and that makes me a brand loyalist.

Andrew Binns, Head of Digital and Innovation at AstraZeneca UK

How interactive media can improve HCP engagement

Interactive media improves engagement when it does one thing well: reduce effort while increasing clarity and confidence. Instead of asking HCPs to read long pages and assemble meaning themselves, personalized interactive experiences guide them through key information and route them to the underlying sources for verification.

1. Interactive videos

Perfect for educational content and explainers for new treatments — similar to Netflix’s interactive TV shows. 

Portals are not doing great in meeting healthcare professionals’ demands for learning opportunities. In fact, just 30% of portals offer learning tools, while many HCPs demand them.

Adding interactive videos to the mix can be a great way to increase interactivity, engagement, and repeat visits.

Interactive videos can be used for non-accredited learning, webinars, or for transforming lengthy PDFs into easily digestible videos with chapters and quizzes.

2. Dosing and safety quizzes

These interactive tools are great for adapting classic documents and brochures into digital formats that better meet the needs of HPCs (especially when they are low on time).

A good example is PfizerForAll’s migraine screener helps users determine their treatment eligibility through a simple interactive quiz. A similar approach can be used for HCPs looking to find resources.

3. Patient resource generators using digital tools

Allow doctors to customize patient education materials with a few clicks, filtering content based on specific patient characteristics.

One high-impact area is education — here are examples of interactive content for HCP continuing education that go beyond the webinar.

The insight here is clear: effective personalization doesn’t need to be overtly requested—it should simply work in the background. Healthcare professionals will appreciate a portal that intuitively adapts to their needs without demanding extra effort.

What powers HCP engagement at scale: data-compliant personalization and omnichannel orchestration

The engagement ladder only becomes repeatable when you can measure behavior, learn from it, and improve the experience across channels. That’s what data enables: better decisions about what to build and what to fix.

Cross-industry pattern: use behavioral data to improve journeys

High-performing digital products treat data as a feedback loop:

• They track where users drop off
• They identify the actions that correlate with retention
• They personalize discovery based on observed intent

How to translate it into pharma HCP engagement

In pharma, data should help you do three practical things:

• Diagnose engagement friction

Where do HCPs drop off? Registration, search, content pages, downloads, events?

• Segment by intent, not just specialty

Different users come with different goals. Engagement improves when the portal directly supports those tasks.

• Power-compliant personalization

Use portal behavior (what they read, what they search, what they download) to improve relevance, while staying within regional rules and consent requirements.

This is where AI behavioral insights can help you move from reporting to predicting what drives adoption and return visits.

What data to collect?

To build an engagement loop, you typically need inputs from:

• Portal analytics — navigation paths, search queries, content interactions
• CRM signals — consented interaction history, channel preferences
• Campaign interactions — email clicks, event attendance, downloads
• Market research insights where available

What to measure?

Tie measurement to the ladder:

• Access — registration completion, login success, time-to-first page
• Activation — time-to-first useful action, first-session task completion
• Value — search success rate, time-to-right resource, downloads/saves
• Habit — 30/60/90-day return rate, repeat usage of modules/series

Cross-industry pattern: meet users where they are

Even with a strong portal, engagement fails if you only show up in one place. Some HCPs prefer digital; others still need field interactions or print materials. The goal is orchestration, not channel purity.

Portals perform best when they’re orchestrated across channels — here’s a strategic guide to improving the HCP omnichannel journey.

How to translate it into pharma HCP engagement strategies 

• Use the portal as the trusted source hub
• Use other channels to route HCPs back to the hub when useful (email → portal update, rep visit → follow-up resource link, webinar → portal recap pack)

What to measure?

• Channel preference signals
• Assisted journeys (email/rep/webinar → portal action)
• Resource reuse across channels (same asset used multiple ways)

What the future holds for the pharma digital landscape

HCP engagement is moving in the same direction as every other mature digital ecosystem: from content delivery to service design. 

HCPs return to portals because they consistently help them to do real work faster, with confidence and trust.

The portals that win treat engagement like a product discipline: reduce friction, accelerate time-to-value, improve discovery, and build repeatable value loops. Then measure and iterate.

If you’re exploring the bigger picture, here’s how AI in HCP engagement is changing pharma’s digital playbook.

The HCP engagement ladder (recap)

• Access — can HCPs get in quickly and find their way without friction?
• Activation — do they complete a first useful action fast or bounce before value shows up?
• Value — do they reliably find relevant, trusted resources that support real clinical tasks?
• Habit — do you give them clear reasons to return?

Implementation checklist (recap)

If you want to increase adoption and return visits, start here:

1. Remove access friction

• Shorten the registration process and reduce login failure points
• Make the portal’s value proposition obvious in the first screen

2. Engineer activation

• Define “first useful action” and optimize for it
• Use progressive profiling instead of front-loading forms

3. Make discovery effortless

• Fix search and taxonomy so HCPs can find resources fast
• Add “next best content” and “new since last visit” modules

4. Build repeatable value loops

• Use micro-learning and interactive media
• Turn one-off resources into series and update packs

5. Close the loop with data

• Measure engagement by stage 
• Use behavioral signals to improve relevance and compliant personalization over time

Cross-industry lessons are useful, but the advantage comes from translation, not imitation. The goal isn’t to make pharma portals feel like Amazon or Netflix.

The goal is to borrow experience patterns that reduce effort and increase returns, then apply them in a compliant way to the realities of HCP work.

FAQ: HCP engagement in pharma portal

The post HCP engagement in pharma: how to drive adoption and return visits appeared first on Digitalya.

With 40% of HCPs using AI to support diagnosis, pharma companies must rethink their portal structure.

Your HCP portal may become invisible if you don’t optimize it for generative engines. This can happen even if the science is strong.

What Is Generative Engine Optimization (GEO)?

Generative Engine Optimization (GEO) means improving digital content so AI search systems can understand, extract, summarize, and cite it.

Unlike traditional SEO, which targets search rankings, GEO aims to earn citations in AI-made answers.

GEO vs. Traditional SEO

A Practical Guide to Generative Engine Optimization (GEO) for HCP Portals

In a world where more people use ChatGPT before Google, even top pharma content can become hard to find.

It may be easy to dismiss artificial intelligence in pharma and how HCPs search for information.  

But we are heading toward a world where AI searches will be the norm.

Many portals still rely on basic SEO. This approach makes it difficult for HCPs to efficiently find relevant information and answers to their queries. However, Generative Engine Optimization (GEO) for HCP portals addresses this limitation.

Unlike traditional search engines, AI tools don’t return a list of blue links, but they summarize, cite, and synthesize.

People aged 18 to 34 use ChatGPT more often than Google. That’s what a recent Semrush research reveals about how people interact with ChatGPT. 

On top of that, people aged 35-44 are becoming more accustomed to using AI chatbots.

HCPs are no different. 52% are using AI for searching, summarising, or analysing scientific literature, according to Graphite Digital’s research.

The gap is closing. Younger healthcare professionals are more comfortable with technology, and they’ll dominate the workforce within a few years.

The Problem: Pharma’s SEO Playbook Is Outdated

Pharmaceutical websites and HCP portals have prioritized long-form content, static PDFs, slide decks, and compliance-heavy gated access.

These formats work better when the traffic source is sales reps. Or when the main focus is on traditional Google indexing and keyword strategies.

However, these assets often resemble regulatory documents and provide little value to AI systems. AI chatbots prioritize clarity, structure, and user-centric responses.

An Eolas research found that over 45% of clinicians had used AI to answer clinical questions.

Healthcare professionals increasingly use AI as a complementary tool and rely on AI generated responses. They are consulting it for insights while cross-checking its recommendations against their expertise or reliable sources.

That’s a structural shift.

Delivering clear value through short, interactive content for HCPs is now a must. It should meet their high expectations and limited time.

AI chatbots won’t summarize or cite a gated PDF containing dosing guidelines.

And if it’s invisible to AI, it might as well not exist.

Out Now

HCP Portal Audit: Find Out Where Your Portal Falls Behind in 2026

Get access to a comprehensive audit and in-depth analysis of 28+ HCP portals across Europe and the US.

Get the report

1. The New Search Reality: From SEO to Generative Engine Optimization (GEO)

Pharma companies have primarily relied on traditional SEO tactics.

That meant:

• Keyword-focused landing pages
• Long-form content
• PDFs filled with clinical detail
• Backlinks from trusted websites

But behavior is changing. The SEO focused world in which HCPs were willing to browse multiple Google searches is fading.

Generative Engine Optimization (GEO), also known as AI Search Optimization (AISO), is the next evolution.

Unlike traditional SEO, GEO is not about ranking in Google’s top 10 links.

GEO means optimizing content so AI systems can cite, summarize, or recommend it directly in their answers.

That means:

• Clear structure
• Machine readability
• Trust signals
• Evidence-backed claims

A recent CMSWire article explains it well:

“Traditional SEO relies on search engines crawling links and ranking content by relevance. AI search, by contrast, synthesizes information across multiple sources to deliver direct answers, and often only credits a few.”

CMSWire

Is SEO dead?

No, and it likely won’t be for a long time. It should stay in your digital marketing toolkit.

Strong SEO is now a prerequisite for effective GEO.

AI agents often start with top-ranked content when generating summaries or answering questions.

That means AI tools are much more likely to see and cite your page if it already ranks on Google’s first page.

However, SEO today encompasses more than just keyword density or backlinks.

To succeed in this new hybrid world of traditional and AI search, SEO must evolve. It must:

• Focus on comprehensive topic coverage that addresses real user (and HCP) intent
• Creating content that is structured and easy-to-summarize, instead of long pages or gated PDFs
• Demonstrate expertise, trust, and originality, which both search engines and AI models reward
• Include question-based phrasing that mimics the natural way professionals now ask AI tools for help

So, search engine optimization isn’t dead; it’s just getting smarter.

Think of it this way:

Good SEO gets you indexed. Great GEO gets you cited.

As Tom Vaughton, CEO of SEO agency Varn, said during our webinar, “HCP portals that actually work”

“If your HCP portal content isn’t optimized for how doctors and HCPs search today, it’s invisible, even if it’s brilliant.”

Tom Vaughton

2. How AI Search Changes HCP Engagement

More physicians are skipping Google entirely and asking ChatGPT clinical questions.

The Impiricus & CMI Media Group survey found:

• 51% of HCPs use generative AI
• 71% of primary care physicians use AI
• 36% of dermatologists use AI

The research also analyzes how HCPs utilize AI tools:

• 42% Clinical decision support & medical questions
• 32% Documentation & charting
• 10% Drafting emails, letters, & other writing
• 10% Prior authorizations
• 6% Research Summaries

This data shows a major opportunity for pharma portals.

If your content answers the types of structured clinical questions AI systems summarize, your visibility increases dramatically.

The Pharma-Specific GEO Opportunity

Yes, HCP portals must remain gated, especially in the EU. But that doesn’t mean content must be invisible.

Generative Engine Optimization for HCP portals means structuring what can be public without breaching compliance.

Examples:

• Executive summaries of gated content
• Non-promotional scientific insights
• FAQ pages
• Dose comparison tables
• Structured HTML summaries of PDFs
• References to guidelines and publicly available evidence

AI systems prioritize:

• Clear claims
• Evidence-backed statements
• Expert attribution
• Updated content

3. Practical Steps to Optimize Your HCP Portal for GEO

3.1 Structure Content for AI Visibility

AI systems may stop reading after a token limit, as many AI systems operate with timeouts. 

Here’s how to structure your content for maximum AI visibility:

Place key information high on the page

Important facts, takeaways, and answers should be at the top of each page before brand messages.

Use semantic markup (schema.org)

Structured data, such as FAQ, Breadcrumb, and VideoObject, helps AI systems understand the type and purpose of your content.

For pharma-specific content, consider adding markup around authorship (Person) and medical terms where possible.

Create teaser pages for gated content

Create public-facing teaser pages with summaries of gated documents: 

• Key findings
• Bullet lists
• Key visuals
• Call to action buttons

AI will more likely index the value of your content without breaching compliance.

Optimize for conversational, question-style searches

AI tools answer natural questions, such as “What are the latest safety concerns with SGLT2 inhibitors?”

Reflect this behavior in your content. 

Include:

• Q&A sections
• Conversational headings
• Long-tail questions

Use clear headings, bullet points, and relevant visuals

AI loves scannable formats. Use:

• H2/H3 headings
• Concise paragraphs
• Bullet lists
• Charts
• Infographics
• Annotated diagrams
• Embedded explainer videos

If PDFs are required, duplicate key content in HTML summaries

If you must use PDFs, create an HTML page summarizing their key points in structured text. 

This approach enhances both SEO and generative search, improving the user experience for mobile visitors.

3.2 Demonstrate Authority, Trust & Relevance

AI tools prioritize reliable sources.

To become a credible source of information, an HCP portal must demonstrate clinical rigor, professional expertise, and transparency. Leveraging HCP behavioral insights and demonstrating a deep understanding of HCP needs is crucial to signaling trust.

Here’s how to build that trust:

Display E-E-A-T signals: Expertise, Experience, Authoritativeness, Trustworthiness

Originally coined by Google, these signals influence AI search tools. 

One key step is to ensure your content reflects:

• Medical expertise (e.g., authored by specialists)
• Real-world experience (e.g., clinician insights or case studies). 

Display author names and credentials (MD, PhD). Include their professional group and expertise on both teaser and gated content.

AI tools utilize this metadata to determine if the content is medically reliable and worthy of citation.

Next, show your content is trustworthy by referencing:

• Respected healthcare professionals
• Clinical guidelines
• Medical journals
• Product SPCs (Summaries of Product Characteristics). 

Use up-to-date, comprehensive, and well-cited content

AI systems value recency and thoroughness. Your content should:

• Reflect the latest data, 
• Include clear guidelines and treatment options
• Include citations and links to sources

AI tends to prefer content sources that cover a topic in depth and clearly reference supporting evidence.

3.3 Technical Readiness for GEO

AI systems have limited patience for:

• Slow pages
• Messy code
• Poor navigation

Here’s how to make your portal technically ready:

Get indexed: check robots.txt, sitemaps, and firewall rules

Allow limited crawler access by setting up proper rules in robots.txt, submitting structured sitemaps, and whitelisting trusted AI crawlers (where appropriate).

Use intuitive navigation and ensure fast loading

Our HCP portal Audit and Report shows that most portals offer cumbersome access, including lengthy forms and registration processes. 

The Value Gap market research confirms that poor digital experiences are the primary driver of 65% of HCPs reducing or stopping engagement with a pharma company. 

These discourage physicians from signing up, leading to low HCP portal adoption.

Optimize your portal for GEO by including:

• Breadcrumbs (navigation links that show users their current location on a website)
• Easy content filtering 
• Self-personalization features (allowing HCPs to choose the channels, content, and frequency of communication)
• Reduced login steps
• Content summaries
• Fast loading speeds by using compressed images, browser caching, and mobile responsiveness

Create an llms.txt file to manage AI crawler permissions

Similar to robots.txt, the emerging llms.txt (Large Language Models or LLMS crawler rules) standard allows site owners to signal how and whether AI agents can use their content.

While still evolving, adopting this early signals your readiness for AI integration and helps you manage content governance and get brand mentions.

4. Measuring GEO Performance

AI search isn’t a black box. If you know where to look, you can measure the performance of your content across AI platforms.

Here’s how to keep a pulse on your AI visibility.

4.1 Monitor AI-driven traffic and citations

Watch your Google Analytics and Google Search Console for new referrers (e.g., Perplexity.ai or Claude.ai). 

Look for sudden spikes from AI-generated summaries or specific branded queries that resemble AI suggestions.

This way, you can identify which gated pages attract clicks and show what works and what doesn’t.

Lately, SEO tools like Semrush, Ahrefs, and others have added AI visibility features. They allow you to track prompts and see when AI cites your portal’s content. Plus, they offer recommendations to get better results.

4.2 Evaluate engagement: time on page, conversion from teaser to login, downloads

Key metrics to monitor HCP engagement include:

• The time they spend on a teaser page
• The number of document downloads
• Conversions from gated content

If your AI-optimized summaries aren’t converting, revisit the structure, clarity, trustworthiness, or calls to action.

4.3 Constantly update and test content based on performance and AI search trends

Build a content operations loop: 

1. Monitor trends and track prompts 
2. Update low-performing assets and content
3. A/B test different formats or question structures to learn what artificial intelligence chatbots prefer to summarize and cite.

Key Takeaways: Generative Engine Optimization for HCP Portals

• GEO ensures visibility in AI-generated answers.
• SEO remains foundational, but structure now drives citation.
• AI tools prioritize trust, clarity, and evidence.
• Public summaries help people find gated content.
• Technical readiness directly impacts AI visibility.

5. Looking Ahead

We’re standing at the edge of a shift that will change how HCPs interact with medical content.

As AI-powered tools are becoming the primary gateway to information. AI search is replacing traditional search engines, rewriting the rules of digital visibility in real time. 

Innovative AI tools are simplifying complex health data, enabling healthcare providers to make informed decisions and enhance engagement.

The question is no longer:

“Are we optimized for Google?”

It’s:

“Are we optimized for Generative Engines?”

Early adopters of Generative Engine Optimization (GEO) will gain:

• Greater AI visibility
• Increased trust
• Stronger HCP engagement
• Competitive advantage

Future-proofing your digital presence starts now:

• Audit your content and technical readiness for AI visibility
• Iterate regularly to keep pace with new tools and behaviors.
• Educate your teams on the principles of GEO and embed them into every new initiative.

Smarter discoverability will define the next generation of HCP engagement.

FAQ: Generative Engine Optimization (GEO) for Pharma

Out now

The State of AI in Pharma: Trends, Benchmarks, and What's Next

Get our exclusive market research, featuring insights from 200+ leaders across the EU, US, and Asia.

Get the new report

The post HCP Portals in the Age of AI Search: A Practical Guide to Generative Engine Optimization (GEO) appeared first on Digitalya.

Despite significant investment, many HCP portals face the same challenge: low adoption and limited engagement from HCPs.

In most scenarios, the challenge lies not in the content, technology, or compliance but in the user experience (UX).

Common UX issues quietly undermine even the most sophisticated digital strategies. This is making portals hard to navigate, time-consuming to use, and frustrating for busy HCPs. When UX fails, HCPs disengage, data quality drops, and digital ROI suffers.

Unlike consumer platforms, HCP portals operate in a uniquely complex environment:

• Strict regulatory and compliance constraints.
• Highly specialized content.
• Multiple-use roles and access levels.
• Time-poor users making critical decisions.

HCPs don’t browse pharma portals for inspiration. They log in with a clear purpose: to quickly find specific information, complete a task, or access relevant resources. If the experience feels slow, confusing, or cluttered, they leave and often don’t come back.

Poor UX in HCP portals leads to:​

• Low HCP adoption after launch.
• Shallow engagement and short session times.
• Underused features and content.
• Reduces trust in digital initiatives.

On the other hand, a well-designed portal helps pharma companies:

• Increase portal adoption organically.
• Improve content discoverability.
• Support omnichannel strategies more effectively.
• Collect higher-quality data and insights.

In short, UX is the bridge between compliance-driven platform design and real-world HCP behavior. When that bridge is weak, everything built on top of it suffers.

2. The most common pain points

Despite differences in therapeutic areas, geographies, and technology stacks, many portals share the same recurring UX problems. These issues are rarely the result of poor execution. They usually stem from structural constraints such as compliance requirements, legacy systems, and complex internal stakeholder dynamics.

Below are the most common UX issues observed in pharma portals. Let’s break down each issue, explain its root causes, and outline practical remediation strategies to improve clarity.

2.1 Overloaded dashboards and information density

The issue

​Pharma portals often show too much information. Dashboards become crowded with various content, all vying for attention.​

Impact on HCP experience

• Increased cognitive load.
• Difficulty identifying primary actions.
• Longer time to first meaningful interaction.

For time-constrained HCPs, an overloaded dashboard creates friction before value is delivered.

How to fix

• Apply clear visual hierarchy and prioritization.
• Limit dashboards to 1-3 primary actions per user role.
• Use progressive disclosure to reveal secondary information only when needed.
• Design role-based dashboards aligned with real HCP workflows.

2.2 Poor navigation and content findability

The issue

Navigation often reflects internal taxonomies rather than user needs. Branded or regulatory terms shape menus, confusing HCPs.

​Additionally, portals may rely heavily on deep menu hierarchies that require multiple clicks to reach essential information.

​Our HCP Audit and Report has revealed that many HCP portals lack basic navigation features (like breadcrumbs for context or filtering options).

Impact on user journey

• Difficulty locating relevant content.
• Increased reliance on search.
• Higher bounce rates and session abandonment.

When users can’t quickly find what they need, they perceive the portal as inefficient, regardless of content quality.

How to fix

• Redesign information architecture based on user tasks, not internal structures.
• Simplify navigation levels and reduce depth.
• Implement robust, optimized search with filters and suggestions.
• Use language that reflects how HCPs think and search for information.

While many HCP portals provide a solid foundation with diverse content and reliable information, design and user experience can be significantly improved.

Navigation remains a critical weakness; they often lack advanced features such as filtering and breadcrumbs that make content easier to find.

To create impactful portals, pharma companies must prioritize user-centricity by conducting thorough user testing to address unclear labeling and complex navigation. Moreover, portals should be regularly improved, with regular feedback and iterative enhancements.

Quote from the HCP Audit and Report

2.3 One-size-fits-all experience

The issue

Many portals have the same interface and structure for all users. They do not consider the different needs of healthcare professionals.

Impact on user behavior

• Perceived lack of relevance.
• Reduced engagement over time.
• Missed opportunities for meaningful personalization.

A generic experience rarely supports advanced use cases such as targeted education or contextual decision support.

How to fix

• Introduce role- and specialty-based UX patterns.
• Adapt content visibility based on user profiles and permissions.
• Personalize interfaces using behavioral and contextual data.
• Focus on relevance rather than content volume.

2.4 Complex log-in and access flows

The issue

Security needs often lead to complex login and registration processes, implemented with little UX focus.

Lengthy forms, unclear instructions, and poorly designed multi-step flows create significant friction before users access any value.

Impact on digital experiences

• High drop-off rates during registration.
• Delayed first value moment.
• Negative perception before engagement begins.

First impressions are critical, and onboarding is often where portals lose users permanently.

How to fix

• Streamline onboarding to the minimum required steps.
• Clearly communicate why you need this information.
• Provide visual progress indicators.
• UX-test log-in flows with real users.

2.5 Poor mobile and tablet experiences

The issue

Many organizations still design portals for desktop use only. Mobile and tablet versions often lack touch-optimized functionality for real-world use.

Impact on user engagement

• Difficult navigation on tablets and mobile devices.
• Reduced usability during clinical workflows.
• Lower engagement outside traditional office settings.

Given how frequently HCPs use tablets and smartphones, this represents a significant usability gap.

How to fix

• Adopt a mobile-first UX design approach.
• Optimize layouts for touch-based interaction.
• Prioritize performance and loading speed.
• Test usability across devices commonly used by HCPs.

2.6 Ignoring accessibility and inclusivity

The issue

Accessibility is often treated as a compliance checkbox rather than a core UX principle. Low contrast, small typography, complex forms, and poor keyboard navigation are common issues.

Impact on HCP experience

• Reduces usability for users with visual or motor impairments.
• Increased compliance and legal risk.
• Exclusion of a portion of the user base.

Accessibility shortcomings affect usability for everyone, not just those with declared disabilities.

How to fix

• Design according to WCAG guidelines.
• Conduct accessibility audits regularly.
• Use inclusive typography, contrast, and interaction patterns.
• Integrate accessibility checks into the design and development process.

2.7 UX designed without real HCP input

The issue

Organizations frequently rely on assumptions when designing medical portals, leading to rare or reactive UX improvements.

The HCP Portal Audit and Report revealed many cases in which features or elements that healthcare providers would find necessary or useful were absent from the HCP portals used.

For example, 80% of HCPs expressed interest in bookmarking features, but only 8.3% of HCP portals provided them.

Impact on HCP experience

• Misalignment with real-world workflows.
• Persistent usability issues.
• Reduced long-term adoption.

Without continuous feedback, portals fail to evolve alongside user needs.

How to fix

• Conduct regular usability testing with HCPs.
• Use qualitative and quantitative UX data.
• Iterate regularly rather than relying on large redesigns.
• Treat UX as an ongoing capability, not a one-time project.

3. How to approach UX improvement in pharma

Improving UX in pharma portals is not about copying consumer apps or removing necessary controls. It requires a principled approach that balances usability, compliance, and technical reality.

Let’s discuss the core design principles that consistently drive better adoption and engagement on pharma portals.

3.1 Design for real HCP workflows, not internal structures

A common mistake in pharma portal UX is designing around internal teams, brands, or content ownership. While this may simplify governance, it rarely reflects how HCPs actually work.

Effective UX starts by understanding:

• What tasks HCPs are HCPs trying to complete?
• When and where do they access the portal?
• What information do they need at each stage?

Portals around real workflows reduce friction and shorten the path to value. This principle requires close collaboration between UX designers, product owners, and medical teams to translate clinical realities into intuitive digital experiences.

3.2 Prioritize clarity over feature volume

In regulated environments, it is tempting to repeatedly add features to justify investment or satisfy multiple stakeholders. Over time, this leads to bloated interfaces that are difficult to navigate.

A principled design process prioritizes:

• Clear primary actions.
• Focused interfaces.
• Minimal cognitive load.

Clarity does not mean removing functionality. It means structuring features to align with user priorities and reveal complexity only when necessary.

3.3 Embed compliance into the UX, not on top of it

Compliance requirements are often implemented as additional layers that disrupt the user journey. Treating compliance as an afterthought makes it a visible obstacle rather than an integrated part of the experience.

Better outcomes are achieved when:

• You consider compliance from the earliest design stages.
• You translate regulatory constraints into clear, user-friendly interactions.
• Transparently explain mandatory steps.

When users understand why certain actions are required, friction decreases and trust increases.

3.4 Design for progressive engagement

Not all HCPs engage with portals at the same level. Some log in occasionally for specific information, while others become frequent users.

Effective HCP portal UX supports this spectrum by:

• Allowing quick access to essential content for light users.
• Offering deeper functionality for advanced users.
• Avoiding forced engagement patterns.

Progressive engagement enables portals to grow with the user rather than overwhelming them from the first interaction.

3.5 Treat UX as a continuous capability

UX in pharma portals should not be a one-off design phase followed by years of stagnation. User needs, regulations, and digital expectations evolve constantly.

A mature UX approach includes:

• Continuous usability testing.
• Ongoing measurement of user behavior.
• Iterative improvements based on data and feedback.

This principle shifts UX from a project mindset to a useful capability embedded in the portal’s lifecycle.

3.6 Measure UX success with meaningful metrics

Traditional pharma websites’ metrics, such as logins or page views, provide limited insight into user experience quality. Thorough UX improvement requires more meaningful indicators.

Effective metrics include:

• Task completion rates.
• Time to first value.
• Feature adoption per user engagement.
• Drop-off points in critical flows.

These metrics allow teams to identify friction points and prioritize improvements with clear business impact.

4. Turning UX improvements into business impact

In pharma portals, UX improvements are often viewed as subjective or aesthetic. In reality, they have direct and measurable consequences for both digital performance and broader commercial and medical objectives.

Pharma organizations typically see improvements across several critical dimensions when they address UX issues regularly.

• Increased HCP adoption and retention

An intuitive, user-centric, relevant, and efficient portal lowers the barrier for new users. Clear onboarding, simple interfaces, and easy navigation help healthcare professionals return. This prevents them from leaving the platform after their first use.

• More effective content usage

Improved UX increases content discoverability and contextual relevance.  Users are more likely to access, understand, and use educational materials, clinical resources, and services when they are easy to find and clearly presented.

• Higher-quality data and insights

When a portal improves user experience, HCPs complete more interactions, forms, and workflows accurately. This leads to better-quality data, more reliable analytics, and stronger foundations for personalization and omnichannel strategies.

• Better alignment between digital investment and ROI

UX-driven portals maximize the value of existing technology and content investments. Instead of adding new features, organizations can unlock impact by improving how users interact with what already exists.

Good pharma UX design changes portals from simple compliance tools into valuable digital assets. These assets help build long-term trust and engagement with healthcare professionals (HCPs).

5. Conclusion

A lack of expertise rarely causes common UX issues in pharma portals. They are the result of complex constraints, competing priorities, and evolving digital expectations.

By focusing on clear, thorough UX design grounded in real HCP workflows, pharma companies can improve portal use. This approach helps boost engagement and business results while maintaining compliance.

Addressing UX is not about making pharma portals look better. It’s about making them work better for the people they are built for.

Suggested further reading:

• Cross-industry inspiration to improve the HCP digital experience
• The hidden reasons behind low HCP portal adoption
• The anatomy of building an HCP portal

The post Common UX issues in pharma portals (and how to fix them) appeared first on Digitalya.

1. Pharma’s AI moment requires strategy, not hype

AI has rapidly moved from an experimental curiosity to a core capability shaping how pharma communicates, operates, and delivers scientific value. Every team, from medical affairs to commercial and R&D to operations, feels pressure to “do something with AI.”

Teams test tools, developers multiply proofs of concept, and vendors promise transformative impact.

Yet, despite this momentum, many organizations aren’t seeing meaningful results. The reason is simple: most AI initiatives begin with hype, not strategy.

Instead of focusing AI investment on real business problems, teams often start by exploring tools. They may launch pilots or react to internal excitement. The outcome is predictable — excitement without direction, adoption without alignment, and innovation without measurable value.

Leadership buy-in is the most developed factor in organizational AI readiness, according to our state of AI in pharma report. However, other important areas are not as developed. 

These areas include Regulatory and Compliance Alignment, Standard Operating Procedures (SOPs) and AI Procedures, Data Governance and Availability, and AI literacy and skills. All of these are at the bottom of the AI readiness scale.

Pharma’s moment is not about adopting more AI. It’s about choosing where AI actually matters.

To provide value, an AI strategy must set clear priorities. It should also address data and governance issues. Finally, it needs to create ways for compliant and scalable implementation. 

Without this foundation, even the most advanced models become isolated experiments — impressive in demos, but disconnected from daily workflows and organizational goals.

The pharmaceutical industry needs a strategic approach that turns AI from scattered activity into sustained, enterprise-level impact.

2. What “value” means in pharma AI

Value from AI isn’t about novelty, automation for its own sake, or how advanced a model appears. We measure value by how effectively AI supports scientific accuracy, compliance, operational efficiency, and meaningful engagement with healthcare professionals.

Unlike other industries, where people often celebrate experimentation, pharma’s high-stakes environment demands outcomes that are reliable, traceable, and directly tied to organizational goals.

Real value emerges when AI addresses specific pressure points across teams:

Operational value

Reduce manual work, speed up content creation and review, improve consistency, and let experts focus on essential tasks. When medical writers, MLR reviewers, and commercial teams save hours, AI becomes a genuine accelerator.

Medical and scientific value

Enhancing the clarity, accuracy, and consistency of scientific communication. AI should help find insights faster. It should also summarize the literature better. Finally, it must keep medical content aligned with evidence and internal guidelines.

Commercial and engagement value

Improving HCP engagement through better personalization, more relevant content, and faster response times. Value is not the AI output itself, but the impact on understanding and serving healthcare professionals more effectively.

Organizational value

Enabling teams to work with shared knowledge, better governance, and more predictable workflows. AI becomes a valuable asset when it makes medical, legal, and commercial functions easier. It should not add more complexity.

AI can become a strategic capability that improves how pharmaceutical companies communicate, operate, and deliver scientific impact.

Out Now

HCP Portal Audit: Find Out Where Your Portal Falls Behind in 2026

Get access to a comprehensive audit and in-depth analysis of 28+ HCP portals across Europe and the US.

Get the report

3. The pillars of an AI strategy that works in pharma

Designing an AI strategy that delivers value needs a structured approach that aligns AI with business priorities, operational realities, and regulatory expectations.

A. Business alignment: start with problems, not tools

Too many projects begin with the question “What can AI do for us?” instead of “Where are we losing time, consistency, or insight today?“

As James Turnbull said in our webinar Is Pharma Ready for AI at Scale?:

Companies need to move towards a bottom-up approach in which leaders work with the team to identify AI use cases that actually make sense and deliver value.

James Turnbull, CEO of medcomms agency Camino Communications

A value-driven AI strategy begins by identifying high-friction areas across medical, commercial, and operational teams. These workflows are often repetitive, manual, slow, or rely on expert knowledge. Compliance and governance rules also limit them.

Once these challenges are mapped, AI use cases should be prioritized based on three criteria:

• Business impact — will this materially improve efficiency, quality, or engagement?
• Feasibility — is the data available and sufficiently structured?
• Compliance fit — can this be implemented within regulatory constraints?

When organizations connect AI to business results, they find it easier to get support from leaders. They can also align stakeholders and set clear success metrics.

B. Data readiness: the foundation of all AI

AI strategies rise and fall on the quality of the data beneath them. In life sciences, data is abundant, but rarely unified. Scientific publications, internal guidance, CRM records, regulatory documentation, and medical content often live in disconnected systems.

A mature AI strategy treats data as a strategic asset. This means investing in:

• Structured and well-governed data sources
• Clear taxonomies and metadata
• Access controls and versioning
• Data quality standards aligned with medical and regulatory requirements

Without this foundation, AI outputs become inconsistent, unreliable, or difficult to validate. With it, AI can surface insights faster, generate content with greater confidence, and support traceability.

C. Technology architecture: choose tools that scale

Choosing the right AI architecture is about designing systems that can grow with the organization. In pharmaceutical companies, AI should fit well with current digital systems. This includes CRM platforms, document management, and MLR workflows.

A scalable architecture typically includes:

• Large AI models or smaller domain-specific models
• Retrieval-augmented generation to ground outputs in trusted sources
• Secure APIs and modular components
• Integration layers connecting AI capabilities to everyday tools

This approach prevents AI from becoming a collection of disconnected tools. Instead, it enables pharma teams to reuse components, expand capabilities, and maintain consistency across use cases.

D. Responsible & compliant AI: pharma’s non-negotiable framework

Compliance is often seen as a constraint on innovation. In reality, it’s what makes sustainable AI adoption possible. An effective AI strategy embeds responsibility and governance from the start, and not as an afterthought.

This includes:

• Clear AI governance frameworks aligned with MLR processes
• Defined rules for content generation and review
• Audit trails, version control, and explainability
• Human-in-the-loop validation for all high-impact outputs

Compliance and creativity don’t need to pull in opposite directions. AI can take friction out of the process, spotting risks early, streamlining approvals and supporting smarter content reuse. Combined with a robust design system, it can also bring consistency and scalability, giving teams the freedom to create at speed while staying within brand and regulatory guardrails. In this way, compliance stops being the brake pedal and becomes the framework that lets innovation move faster, with trust built in.

Rob Verheul, CEO of design agency Graphite Digital

Responsible AI builds trust. When medical, legal, and commercial stakeholders trust the system, adoption accelerates and innovation becomes repeatable rather than risky.

E. People, change & process: strategy is not only technical

Even the best-designed AI strategy will fail without human adoption. AI changes how people do their work, and that requires clear communication, training, and process design.

Successful pharma companies focus on:

• Clearly defining where AI assists and where human judgment remains essential
• Training teams to use AI confidently and responsibly
• Embedding AI into existing workflows rather than forcing new ones
• Establishing feedback loops to regularly improve outputs

AI should reduce friction, not create it. When teams feel supported instead of replaced, they accept AI as a helpful part of their work. This leads to lasting impact through strategy.

4. High-value use cases pharma should prioritize first

High-value use cases share three characteristics:

• They address real operational friction
• They fit within existing compliance frameworks
• They deliver measurable impact in a relatively short time frame

Pharma companies should focus on using AI to quickly improve consistency, support teams, and reduce workload.

A. Medical affairs & scientific content

Medical and scientific teams are often the most constrained by time, volume, and complexity. AI can deliver significant value here by acting as an augmentation layer, not a replacement for scientific expertise.

High-impact uses include:

• Literature and evidence briefs — helping teams synthesize vast amounts of scientific content faster
• Congress insights automation — extracting key themes, questions, and trends from events
• MLR pre-checks — identifying potential compliance issues before formal review

Manuel Mitola, former pharma leader and currently AI strategist at ctcHealth, sees a significant trend towards AI in medical departments:

The value lies in accelerating workflows and improving consistency, while keeping scientific accuracy and oversight firmly in human hands.

B. Commercial & HCP engagement

Commercial teams face increasing pressure to deliver relevant, personalized experiences to healthcare professionals across more channels with fewer resources.

Priority use cases include:

• Personalized content generation — tailored to HCP’s speciality, interests, and engagement history
• Message optimization — ensuring consistency across channels and regions
• Predictive insights — helping teams anticipate HCP needs and engagement patterns
• Multichannel orchestration support — aligning messaging across email, CRM, and digital touchpoints
• AI-powered chatbots — provide support and information in real time

Here, value is measured by improved relevance, engagement quality, and strategic focus.

C. Internal operations

Some of the fastest AI wins in pharma come from internal operations. We often overlook these areas in favor of more visible external use cases.

High-value applications include:

• Enterprise knowledge retrieval — enabling teams to quickly find validated internal documents, guidance, and SOPs
• Workflow automation — reducing repetitive administrative tasks
• Document classification and tagging — improving accessibility and governance
• Internal Q&A assistants — supporting onboarding and cross-functional collaboration

These use cases may not seem exciting, but they provide strong returns. They save time, reduce problems, and improve teamwork.

James Turnbull shared a few projects he worked on that provide real value:

AI has the most significant impact in pharma when it starts by solving real problems.

Conclusion

AI has reached a turning point. The question is not if organizations should invest in AI. It is about how they can create a plan that provides real, measurable value.

Pharma companies that see AI as just a set of tools will keep facing problems. They will have scattered projects and little impact.

Those who see AI as a key tool will benefit greatly. When AI aligns with business goals, it can be part of daily tasks. This responsible use of AI will boost efficiency, enhance scientific communication, and improve connections with healthcare professionals.

Designing an AI strategy that delivers value is not about moving faster than everyone else. It’s about moving deliberately, with purpose and structure. The leaders who get this right today will be the ones shaping how pharma operates, communicates, and innovates tomorrow.

Out now

The State of AI in Pharma: Trends, Benchmarks, and What's Next

Get our exclusive market research, featuring insights from 200+ leaders across the EU, US, and Asia.

Get the new report

The post How to design an AI strategy for pharma that delivers true value appeared first on Digitalya.